BioCentury | Apr 4, 2014
Top Story

Corium raises $52 million in IPO

...Inc. (Woodcliff Lake, N.J.). Corium also supplies products that use its delivery technology to The Procter & Gamble Co....
BioCentury | Mar 25, 2014
Financial News

Corium sets IPO range

...Inc. (Woodcliff Lake, N.J.). Corium also supplies products that use its delivery technology to The Procter & Gamble Co....
BioCentury | Mar 6, 2014
Financial News

Drug delivery play Corium files for IPO

...Inc. (Woodcliff Lake, N.J.). Corium also supplies products that use its delivery technology to The Procter & Gamble Co....
BioCentury | Sep 2, 2013
Strategy

Back to School 2013: Facing reality

For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector, FDA , EMA and Japan's Pharmaceuticals and Medical Devices Agency are...
BioCentury | Apr 15, 2013
Company News

TheraTech, P&G sales and marketing update

...0.05, 0.075 and 0.1 mgs. Price wasn't disclosed. TheraTech Inc. (THRT), Salt Lake City, Utah Procter & Gamble Co....
BioCentury | Dec 17, 2012
Strategy

Teva's puzzle pieces

...space, Teva has found synergies between generics and OTC medicines via its one-year-old partnership with Procter & Gamble Co....
...Pink:MBLTY), Melbourne, Australia MultiGene Vascular Systems Ltd. , Haifa, Israel NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark Procter & Gamble Co....
BioCentury | Jul 23, 2012
Company News

Somaxon, Mylan, Zydus deal

...certifications that the patents are invalid, unenforceable and/or not infringed (see BioCentury, June 13, 2011). Procter & Gamble Co....
BioCentury | May 14, 2012
Strategy

Outcomes trumping volume

...what contract structure will work best. One of the earliest began in January 2008, when Procter & Gamble Co....
...taken Actonel for nine months, 15 had fractures that met the criteria for reimbursement from P&G...
...in December 2010 for reasons unrelated to the program itself. These included the acquisition of P&G's...
BioCentury | Apr 9, 2012
Company News

Somaxon, P&G deal

...to exercise its option to negotiate for OTC rights to Somaxon's insomnia drug Silenor doxepin. P&G...
...negotiation under a 2010 U.S. co-promotion deal. Somaxon ended the deal last year, but extended P&G's...
...$16.2 million in 2011 net sales for Silenor. Somaxon Pharmaceuticals Inc. (NASDAQ:SOMX), San Diego, Calif. Procter & Gamble Co....
BioCentury | Jan 16, 2012
Strategy

Rebooting confidence

...Phase II or higher. Commercial deals also expanded the company's footprint. Last year, Teva and Procter & Gamble Co....
...BSE:NATCOPHAR), Hyderabad, India Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer Inc. (NYSE:PFE), New York, N.Y. Procter & Gamble Co....
Items per page:
1 - 10 of 236
BioCentury | Apr 4, 2014
Top Story

Corium raises $52 million in IPO

...Inc. (Woodcliff Lake, N.J.). Corium also supplies products that use its delivery technology to The Procter & Gamble Co....
BioCentury | Mar 25, 2014
Financial News

Corium sets IPO range

...Inc. (Woodcliff Lake, N.J.). Corium also supplies products that use its delivery technology to The Procter & Gamble Co....
BioCentury | Mar 6, 2014
Financial News

Drug delivery play Corium files for IPO

...Inc. (Woodcliff Lake, N.J.). Corium also supplies products that use its delivery technology to The Procter & Gamble Co....
BioCentury | Sep 2, 2013
Strategy

Back to School 2013: Facing reality

For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector, FDA , EMA and Japan's Pharmaceuticals and Medical Devices Agency are...
BioCentury | Apr 15, 2013
Company News

TheraTech, P&G sales and marketing update

...0.05, 0.075 and 0.1 mgs. Price wasn't disclosed. TheraTech Inc. (THRT), Salt Lake City, Utah Procter & Gamble Co....
BioCentury | Dec 17, 2012
Strategy

Teva's puzzle pieces

...space, Teva has found synergies between generics and OTC medicines via its one-year-old partnership with Procter & Gamble Co....
...Pink:MBLTY), Melbourne, Australia MultiGene Vascular Systems Ltd. , Haifa, Israel NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark Procter & Gamble Co....
BioCentury | Jul 23, 2012
Company News

Somaxon, Mylan, Zydus deal

...certifications that the patents are invalid, unenforceable and/or not infringed (see BioCentury, June 13, 2011). Procter & Gamble Co....
BioCentury | May 14, 2012
Strategy

Outcomes trumping volume

...what contract structure will work best. One of the earliest began in January 2008, when Procter & Gamble Co....
...taken Actonel for nine months, 15 had fractures that met the criteria for reimbursement from P&G...
...in December 2010 for reasons unrelated to the program itself. These included the acquisition of P&G's...
BioCentury | Apr 9, 2012
Company News

Somaxon, P&G deal

...to exercise its option to negotiate for OTC rights to Somaxon's insomnia drug Silenor doxepin. P&G...
...negotiation under a 2010 U.S. co-promotion deal. Somaxon ended the deal last year, but extended P&G's...
...$16.2 million in 2011 net sales for Silenor. Somaxon Pharmaceuticals Inc. (NASDAQ:SOMX), San Diego, Calif. Procter & Gamble Co....
BioCentury | Jan 16, 2012
Strategy

Rebooting confidence

...Phase II or higher. Commercial deals also expanded the company's footprint. Last year, Teva and Procter & Gamble Co....
...BSE:NATCOPHAR), Hyderabad, India Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer Inc. (NYSE:PFE), New York, N.Y. Procter & Gamble Co....
Items per page:
1 - 10 of 236